Literature DB >> 17184394

The costs of future polio risk management policies.

Radboud J Duintjer Tebbens1, Nalinee Sangrujee, Kimberly M Thompson.   

Abstract

Decisionmakers need information about the anticipated future costs of maintaining polio eradication as a function of the policy options under consideration. Given the large portfolio of options, we reviewed and synthesized the existing cost data relevant to current policies to provide context for future policies. We model the expected future costs of different strategies for continued vaccination, surveillance, and other costs that require significant potential resource commitments. We estimate the costs of different potential policy portfolios for low-, middle-, and high-income countries to demonstrate the variability in these costs. We estimate that a global transition from routine immunization with oral poliovirus vaccine (OPV) to inactivated poliovirus vaccine (IPV) would increase the costs of managing polio globally, although routine IPV use remains less costly than routine OPV use with supplemental immunization activities. The costs of surveillance and a stockpile, while small compared to routine vaccination costs, represent important expenditures to ensure adequate response to potential outbreaks. The uncertainty and sensitivity analyses highlight important uncertainty in the aggregated costs and demonstrates that the discount rate and uncertainty in price and administration cost of IPV drives the expected incremental cost of routine IPV vs. OPV immunization.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17184394     DOI: 10.1111/j.1539-6924.2006.00842.x

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  14 in total

1.  Eradicating polio: the dollars and sense.

Authors:  Kimberly M Thompson
Journal:  MedGenMed       Date:  2007-10-15

2.  The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens
Journal:  Medscape J Med       Date:  2008-08-13

3.  The risks, costs, and benefits of possible future global policies for managing polioviruses.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens; Mark A Pallansch; Olen M Kew; Roland W Sutter; R Bruce Aylward; Margaret Watkins; Howard E Gary; James Alexander; Hamid Jafari; Stephen L Cochi
Journal:  Am J Public Health       Date:  2008-05-29       Impact factor: 9.308

4.  Preeradication vaccine policy options for poliovirus infection and disease control.

Authors:  Kimberly M Thompson; Mark A Pallansch; Radboud J Duintjer Tebbens; Steve G Wassilak; Jong-Hoon Kim; Stephen L Cochi
Journal:  Risk Anal       Date:  2013-03-05       Impact factor: 4.000

5.  Modeling poliovirus risks and the legacy of polio eradication.

Authors:  Kimberly M Thompson
Journal:  Risk Anal       Date:  2013-03-28       Impact factor: 4.000

6.  Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.

Authors:  Agustín Ciapponi; Ariel Bardach; Lucila Rey Ares; Demián Glujovsky; María Luisa Cafferata; Silvana Cesaroni; Aikant Bhatti
Journal:  Cochrane Database Syst Rev       Date:  2019-12-05

7.  A systematic review of vaccine preventable disease surveillance cost studies.

Authors:  Ngozi Adaeze Erondu; Lisa Ferland; Betiel Hadgu Haile; Taiwo Abimbola
Journal:  Vaccine       Date:  2019-03-19       Impact factor: 3.641

Review 8.  Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.

Authors:  Kimberly M Thompson; Dominika A Kalkowska
Journal:  Risk Anal       Date:  2020-04-27       Impact factor: 4.000

9.  An economic analysis of poliovirus risk management policy options for 2013-2052.

Authors:  Radboud J Duintjer Tebbens; Mark A Pallansch; Stephen L Cochi; Steven G F Wassilak; Kimberly M Thompson
Journal:  BMC Infect Dis       Date:  2015-09-24       Impact factor: 3.090

10.  Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.

Authors:  Radboud J Duintjer Tebbens; Kimberly M Thompson
Journal:  BMC Infect Dis       Date:  2015-09-24       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.